These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16208601)

  • 1. [Everolimus].
    Michels G; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2263-5. PubMed ID: 16208601
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecule of the month. Everolimus.
    Drug News Perspect; 2004 Mar; 17(2):142. PubMed ID: 15098068
    [No Abstract]   [Full Text] [Related]  

  • 3. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in cardiac-transplant recipients.
    Banas B; Böger C; Krämer B
    N Engl J Med; 2003 Dec; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
    [No Abstract]   [Full Text] [Related]  

  • 6. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
    Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus: an immunosuppressive agent in transplantation.
    Patel JK; Kobashigawa JA
    Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H; Ross H; Eisen H; Valantine H
    Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Everolimus: immunosuppression with antilymphoproliferative therapy].
    Pascual J
    Nefrologia; 2004; 24(2):112-23. PubMed ID: 15219086
    [No Abstract]   [Full Text] [Related]  

  • 10. Sirolimus for solid organ transplantation in children.
    Gupta P; Kaufman S; Fishbein TM
    Pediatr Transplant; 2005 Jun; 9(3):269-76. PubMed ID: 15910380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 12. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
    Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV
    Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
    J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C; Croom KF
    Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus and long-term outcomes in renal transplantation.
    Campistol JM; de Fijter JW; Nashan B; Holdaas H; Vítko S; Legendre C
    Transplantation; 2011 Aug; 92(3 Suppl):S3-26. PubMed ID: 21799392
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
    Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
    Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md.
    Hiatt WR; Nissen SE;
    Circulation; 2006 Mar; 113(10):e394-5. PubMed ID: 16534016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.